Zai Lab Receives EMA Orphan Drug Designation for New Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Zai Lab announced the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to zocilurtatug pelitecan, the Company's potential first-in-class Delta-like ligand 3-targeting antibody-drug conjugate, for the treatment of pulmonary neuroendocrine carcinomas. The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products, recognizing both the seriousness of neuroendocrine carcinomas and the need for new treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZLAB
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.080
Low
25.70
Averages
47.93
High
74.00
Current: 19.080
Low
25.70
Averages
47.93
High
74.00
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tech Stocks Decline as OpenAI IPO Plans Face Challenges
- OpenAI IPO Delay: OpenAI is reportedly considering postponing its IPO due to the underwhelming performance of SpaceX shares, reflecting ongoing struggles in the tech sector that could further dampen investor confidence and increase market volatility.
- Chinese AI Model Threat: The launch of Z.ai's GLM5.2 model, which is nearly on par with Anthropic's offerings but costs only a quarter of the price, poses a significant threat to U.S. frontier models, potentially leading corporate clients to shift towards cheaper alternatives.
- Corporate Spending Shift: As businesses pull back on high-end AI spending, the demand for AI is not diminishing but rather recalibrating towards lower-cost models, which could negatively impact valuations for OpenAI and Anthropic ahead of their IPOs.
- Significant Market Reaction: Shares of Micron fell by 7%, while AMD and Intel dropped over 4% each in early trading, and Oracle has seen a 19% decline over the past five days, indicating growing concerns about the future of tech stocks.
See More
Anthropic's Suspension of AI Models Sparks Market Concerns
- Model Access Disruption: Anthropic's abrupt suspension of access to its Fable 5 and Mythos 5 models, due to compliance with U.S. export control directives, highlights the risks companies face when relying on external AI models, emphasizing the urgent need for control over AI technologies.
- Significant Market Reaction: Following the Anthropic incident, stocks of Chinese open-source AI labs like MiniMax and Zhipu surged, indicating a growing market interest in downloadable models, as companies seek to avoid being locked into a single vendor by running models on their own infrastructure.
- Industry Shift Trend: Yash Patel, CEO of Applied Compute, noted that more companies are now looking to own their models in response to the shift towards usage-based pricing for AI products, reflecting a growing emphasis on cost-effectiveness and flexibility in AI solution selection.
- Intensifying Global Competition: As open-source models from China gain more adoption, the U.S. faces challenges to its leadership in AI, with models from DeepSeek, Tencent, and Xiaomi surpassing many closed competitors in usage frequency, indicating a changing competitive landscape in the AI market.
See More
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
TIVDAK Approved in China for Cervical Cancer Treatment
- First ADC Approval: TIVDAK is the first antibody-drug conjugate approved in China for the treatment of recurrent or metastatic cervical cancer, marking a significant breakthrough in this area and expected to provide new treatment options for patients.
- Clinical Trial Success: In the global Phase 3 innovaTV 301 clinical trial, TIVDAK demonstrated a statistically significant overall survival benefit, particularly in the China subpopulation, with a 45% reduction in the risk of death, providing strong clinical evidence for its approval in China.
- Broad Regulatory Approvals: TIVDAK has received approvals in multiple regions including the U.S., Japan, and the EU, showcasing the extensive global clinical evidence supporting its availability in China, thereby enhancing its competitive position in the market.
- Significant Market Potential: With approximately 150,000 new cervical cancer cases annually in China, the introduction of TIVDAK will bring hope to a patient population with limited treatment options, and is expected to significantly increase Zai Lab's market share in the Chinese gynecologic oncology sector.
See More
Analysts Favor Investment in China's AI Stocks
- Clear Investment Theme: Analysts agree that despite slowing economic growth in China, AI-related stocks represent the most obvious investment theme right now, with over half of the holdings in new funds focused on semiconductors and high-tech manufacturing, indicating confidence in future growth.
- Weak Consumer Performance: China's retail sales growth in April marked the lowest since the end of the pandemic, highlighting ongoing weakness in the consumer market, while tech stocks exhibit uneven performance, reflecting challenges in the overall economic environment.
- Market Dynamics Shift: In the past two months, a rotation in tech stocks has occurred, with increased investor focus on semiconductors, hard tech, and software, indicating a growing demand for these segments, particularly in the A-share market.
- Divergent Investment Strategies: Mironov holds large positions in Tencent and Alibaba, while Morgan Stanley favors AI model companies like Zhipu and MiniMax, showcasing a divergence in market views on investment strategies and perceptions of sustainable business models.
See More
Zai Lab Leadership Change to Enhance Efficiency
- Executive Departure: Zai Lab's President and COO Josh Smiley has left the company immediately as part of a leadership shake-up aimed at improving operational efficiency, indicating a critical reassessment of management structure at a pivotal time.
- Drug Launch Preparations: This executive change comes just before the anticipated launch of COBENFY™ in China, which may impact the company's strategic direction and competitive positioning in the market.
- Clinical Trial Developments: Zai Lab expects to announce key clinical trial results for its main cancer therapies later this year, which will significantly influence the company's future market performance and investor confidence.
- FDA Fast Track Status: The company's cancer drug Zocilurtatug Pelitecan has received FDA fast track designation, with Phase III enrollment completion targeted for the first half of 2027, highlighting Zai Lab's ongoing advancements in oncology treatment.
See More
Tech Stocks Decline as OpenAI IPO Plans Face Challenges
- OpenAI IPO Delay: OpenAI is reportedly considering postponing its IPO due to the underwhelming performance of SpaceX shares, reflecting ongoing struggles in the tech sector that could further dampen investor confidence and increase market volatility.
- Chinese AI Model Threat: The launch of Z.ai's GLM5.2 model, which is nearly on par with Anthropic's offerings but costs only a quarter of the price, poses a significant threat to U.S. frontier models, potentially leading corporate clients to shift towards cheaper alternatives.
- Corporate Spending Shift: As businesses pull back on high-end AI spending, the demand for AI is not diminishing but rather recalibrating towards lower-cost models, which could negatively impact valuations for OpenAI and Anthropic ahead of their IPOs.
- Significant Market Reaction: Shares of Micron fell by 7%, while AMD and Intel dropped over 4% each in early trading, and Oracle has seen a 19% decline over the past five days, indicating growing concerns about the future of tech stocks.
See More
Anthropic's Suspension of AI Models Sparks Market Concerns
- Model Access Disruption: Anthropic's abrupt suspension of access to its Fable 5 and Mythos 5 models, due to compliance with U.S. export control directives, highlights the risks companies face when relying on external AI models, emphasizing the urgent need for control over AI technologies.
- Significant Market Reaction: Following the Anthropic incident, stocks of Chinese open-source AI labs like MiniMax and Zhipu surged, indicating a growing market interest in downloadable models, as companies seek to avoid being locked into a single vendor by running models on their own infrastructure.
- Industry Shift Trend: Yash Patel, CEO of Applied Compute, noted that more companies are now looking to own their models in response to the shift towards usage-based pricing for AI products, reflecting a growing emphasis on cost-effectiveness and flexibility in AI solution selection.
- Intensifying Global Competition: As open-source models from China gain more adoption, the U.S. faces challenges to its leadership in AI, with models from DeepSeek, Tencent, and Xiaomi surpassing many closed competitors in usage frequency, indicating a changing competitive landscape in the AI market.
See More
Zai Lab's Tivdak Approved in China for Cervical Cancer Treatment
- Drug Approval: Zai Lab's Tivdak has received approval from China's National Medical Products Administration as a treatment for late-line cervical cancer patients, marking a significant advancement for the company in the biopharmaceutical sector.
- Clinical Trial Support: The approval is supported by data from the global Phase 3 trial innovaTV 301, which indicated that Tivdak significantly improved overall survival compared to chemotherapy in the targeted patient population, particularly among Chinese patients.
- Market Potential: With approximately 150,000 cervical cancer diagnoses annually in China, and limited treatment options for recurrent or metastatic cases, the launch of Tivdak offers new hope for these patients and addresses a critical market need.
- Strategic Partnership: In 2022, Zai Lab secured exclusive rights to develop and commercialize Tivdak in mainland China, Hong Kong, Macau, and Taiwan, further solidifying its strategic partnership with Pfizer and Genmab, thereby enhancing its competitive position in the biopharmaceutical market.
See More
TIVDAK Approved in China for Cervical Cancer Treatment
- First ADC Approval: TIVDAK is the first antibody-drug conjugate approved in China for the treatment of recurrent or metastatic cervical cancer, marking a significant breakthrough in this area and expected to provide new treatment options for patients.
- Clinical Trial Success: In the global Phase 3 innovaTV 301 clinical trial, TIVDAK demonstrated a statistically significant overall survival benefit, particularly in the China subpopulation, with a 45% reduction in the risk of death, providing strong clinical evidence for its approval in China.
- Broad Regulatory Approvals: TIVDAK has received approvals in multiple regions including the U.S., Japan, and the EU, showcasing the extensive global clinical evidence supporting its availability in China, thereby enhancing its competitive position in the market.
- Significant Market Potential: With approximately 150,000 new cervical cancer cases annually in China, the introduction of TIVDAK will bring hope to a patient population with limited treatment options, and is expected to significantly increase Zai Lab's market share in the Chinese gynecologic oncology sector.
See More
Analysts Favor Investment in China's AI Stocks
- Clear Investment Theme: Analysts agree that despite slowing economic growth in China, AI-related stocks represent the most obvious investment theme right now, with over half of the holdings in new funds focused on semiconductors and high-tech manufacturing, indicating confidence in future growth.
- Weak Consumer Performance: China's retail sales growth in April marked the lowest since the end of the pandemic, highlighting ongoing weakness in the consumer market, while tech stocks exhibit uneven performance, reflecting challenges in the overall economic environment.
- Market Dynamics Shift: In the past two months, a rotation in tech stocks has occurred, with increased investor focus on semiconductors, hard tech, and software, indicating a growing demand for these segments, particularly in the A-share market.
- Divergent Investment Strategies: Mironov holds large positions in Tencent and Alibaba, while Morgan Stanley favors AI model companies like Zhipu and MiniMax, showcasing a divergence in market views on investment strategies and perceptions of sustainable business models.
See More
Zai Lab Leadership Change to Enhance Efficiency
- Executive Departure: Zai Lab's President and COO Josh Smiley has left the company immediately as part of a leadership shake-up aimed at improving operational efficiency, indicating a critical reassessment of management structure at a pivotal time.
- Drug Launch Preparations: This executive change comes just before the anticipated launch of COBENFY™ in China, which may impact the company's strategic direction and competitive positioning in the market.
- Clinical Trial Developments: Zai Lab expects to announce key clinical trial results for its main cancer therapies later this year, which will significantly influence the company's future market performance and investor confidence.
- FDA Fast Track Status: The company's cancer drug Zocilurtatug Pelitecan has received FDA fast track designation, with Phase III enrollment completion targeted for the first half of 2027, highlighting Zai Lab's ongoing advancements in oncology treatment.
See More
